VOLUME 29 , ISSUE 1 ( January-April, 2025 ) > List of Articles
Shalini Gupta
Keywords : Apolipoprotein B, Dyslipidemia, Low density lipoprotein cholesterol, Non-high-density lipoprotein cholesterol
Citation Information : Gupta S. Latest Indian Guidelines for Dyslipidemia Management: A Biochemist's Perspective. Indian J Med Biochem 2025; 29 (1):45-46.
DOI: 10.5005/jp-journals-10054-0244
License: CC BY-NC 4.0
Published Online: 20-12-2024
Copyright Statement: Copyright © 2025; The Author(s).
The recent lipid management guidelines emphasize using low density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (non-HDL-C), and apo B levels as treatment targets. Out of these, LDL-C is the primary target of lipid management, non-HDL-C is the co-primary and ApoB is the secondary target. One-time estimation of lipoprotein(a) is sufficient presently to assess risk in view of the lack of specific drugs targeting it. Triglyceride levels ≥150 mg/dL in fasting and ≥175 mg/dL in non-fasting samples are considered risk modifiers for atherosclerotic cardiovascular disease. Lipid profile estimation in a non-fasting sample is considered good enough to manage a dyslipidemia patient. The inclusion of risk group-specific target range of lipid profile in biochemistry report format shall be more informative and helpful in ensuring better patient compliance.
© Jaypee Brothers Medical Publishers (P) LTD.
